SRPT Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of 33.55%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Amgen, Inc.'s return on equity of 95.55%.

Sarepta Therapeutics, Inc. has a consensus price target of $20.74, signalling downside risk potential of -4.82%. On the other hand Amgen, Inc. has an analysts' consensus of $331.59 which suggests that it could fall by -4.46%. Given that Sarepta Therapeutics, Inc. has more downside risk than Amgen, Inc., analysts believe Amgen, Inc. is more attractive than Sarepta Therapeutics, Inc..

Sarepta Therapeutics, Inc. has a beta of 0.485, which suggesting that the stock is 51.536% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.454, suggesting its less volatile than the S&P 500 by 54.551%.

Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.74% to investors and pays a quarterly dividend of $2.38 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.

Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Amgen, Inc.'s PE ratio is 26.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 0.93x versus 5.24x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Arrowhead Pharmaceuticals, Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of 6.29%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7%.

Sarepta Therapeutics, Inc. has a consensus price target of $20.74, signalling downside risk potential of -4.82%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $81.92 which suggests that it could grow by 17.71%. Given that Arrowhead Pharmaceuticals, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Sarepta Therapeutics, Inc..

Sarepta Therapeutics, Inc. has a beta of 0.485, which suggesting that the stock is 51.536% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.209, suggesting its more volatile than the S&P 500 by 20.893%.

Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are larger than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $256.5M. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Arrowhead Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 0.93x versus 11.20x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of 20.83%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Johnson & Johnson's return on equity of 33.27%.

Sarepta Therapeutics, Inc. has a consensus price target of $20.74, signalling downside risk potential of -4.82%. On the other hand Johnson & Johnson has an analysts' consensus of $221.54 which suggests that it could grow by 1.4%. Given that Johnson & Johnson has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Johnson & Johnson is more attractive than Sarepta Therapeutics, Inc..

Sarepta Therapeutics, Inc. has a beta of 0.485, which suggesting that the stock is 51.536% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.35% to investors and pays a quarterly dividend of $1.30 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Johnson & Johnson's net income of $5.1B. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Johnson & Johnson's PE ratio is 19.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 0.93x versus 5.63x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of 21.32%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Pfizer Inc.'s return on equity of 10.84%.

Sarepta Therapeutics, Inc. has a consensus price target of $20.74, signalling downside risk potential of -4.82%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 9.8%. Given that Pfizer Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Pfizer Inc. is more attractive than Sarepta Therapeutics, Inc..

Sarepta Therapeutics, Inc. has a beta of 0.485, which suggesting that the stock is 51.536% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.59% to investors and pays a quarterly dividend of $0.43 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Pfizer Inc.'s PE ratio is 15.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 0.93x versus 2.37x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.